Cyclopiazonic acid (CPA) is an indoltetramic acid mycotoxin and is produced by the nearly ubiquitous molds, Aspergillus and Penicillium. CPA produced by these molds has been identi ed in a number of food sources (including, but not limited to, grain, legumes, meat, milk, and cheese) and from parasitic infections of man and other animals. Few incidents of CPA mycotoxicoses have been reported because of the benign nature of the intoxication, the small amounts present, and its effects may be disguised with concurrent a atoxicosis (some toxicity data may have been generated using a atoxin-contaminated CPA). CPA is absorbed in the gastrointestinal tract and following oral administration; it has a halflife of approximately 30 hours and is excreted largely unchanged in the urine and feces. Cyclopiazonic acid is not considered to be a potent acute toxin as its oral LD 50 in rodents is in the range of 30 to 70 mg/kg. Multiple dose studies also show a range of effects in several species and among mammalian models, the pig appears to be the most sensitive with a no-observable-effect level (NOEL) in the range of 1.0 mg/kg/day. The preponderance of evidence from the rat and other test animals supports this dose as a defensible estimate of a no effect level. The target organs of CPA toxicity appear to be muscle, hepatic tissue, and spleen, with a localization in the former, although a more apparent toxic change in the latter two. The toxicity and symptoms of CPA poisoning can be attributed to its ability to alter normal intracellular calcium ux through its inhibition of the reticular form of the Ca 2+ -ATPase pump. CPA was not teratogenic in mice. CPA is not considered a carcinogen and the weight of evidence militates against its characterization as a mutagen. Despite CPA-induced pathological changes ascribed to the spleen or bursa of Fabricius, there does not appear to be an effect on the immune system. In vitro studies imply a potential immunomodulatory effect of CPA, but in all of those reports very high concentrations of CPA were required and none of these ndings have been supported with in vivo studies. Therefore, based on a NOEL of 1 mg/kg/day and accounting for species variation, an appropriate acceptable daily intake (ADI) would be approximately 10 ¹g/ kg/day or 700 ¹g/day. In the context of human exposure, if the uppermost limit of CPA found in cheese is 4 ¹g/g and the average individual consumes 50 g of cheese daily, this allows an intake of 200 ¹g, less than one third of a traditionally established ADI.
INTRODUCTION Historical Perspective
Like many mycotoxins, discovery of the existence of cyclopiazonic acid (CPA) has occurred through a series of fortuitous events and observant investigators. Although a nearly ubiquitous mycotoxin, produced by several species of both Aspergillus and Penicillium, few incidents of animal mycotoxicosis have been reported and only one incident of human poisoning has been associated with CPA (Rao and Husain 1985) . This is not to imply that exposure to CPA is extremely rare, but as a result of its benign nature and because it may often be disguised in the presence of a atoxicosis, exposure may be underreported. Indeed, Miller et al. (1989a) noted that the outbreak of Turkey X disease in Britain in the early 1960s may well have been a combination of a atoxin and CPA, which are often produced concurrently (Trucksess et al. 1987; Lansden and Davidson 1983; Widiastuti et al. 1988; Gallagher et al. 1978; Maggi, Giuliani, and Santicioli 1995) . Further, empirical evidence indicates that commercial samples of CPA may be contaminated with, among other things, a atoxin, yielding sometimes variable and confusing experimental data (Voss 1990) . Table 1 is a partial list of the natural sources of CPA or molds producing CPA once cultured from the primary source. Molds capable of producing CPA are listed in Table 2 . Gallagher et al. 1987 Walnut A. avus Richard and Gallagher 1979 Wheat Balachandran and Parthasarathy 1996a Wheat 2.5 P. cyclopium Rathinavelu and Shanmugasundaram 1984 ¤ CPA production in broth by organisms recovered from these sources. Duke and Steele (1998) .
Regardless of the incomplete blockage of Ca 2+ -ATPase activity, the net effect of CPA in muscle tissues is to produce a negative inotropic and chronotropic effect that becomes apparent in the presenting symptoms of CPA toxicity . Interestingly, several reports have indicated a differential response to CPA in rat myocardial (Agata et al. 1993; Gomez and Potreau 1996; Takahashi et al. 1998 ) and thoracic aorta preps (Tanaka et al. 1997 ) of neonatal and adult origin (Agata et al. 1993) .
Absorption, Distribution and Excretion Absorption
Rats. Cyclopiazonic acid is readily absorbed via intragastric or intraperitoneal routes. Norred et al. (1985) and Norred (1990) administered [ 14 C]CPA to Sprague-Dawley rats either intragastrically (5 mg/kg, 0.6 l Ci/kg) or intraperitoneally (1.0 mg/ kg, 0.12 l Ci/kg); animals were placed in metabolism cages and excrement collected at 1, 3, 6, 12, 24, 48 , and 72 hours after administration; tissues were collected at 72 hours. Peak blood levels of 10% of the dose were detectable within 6 hours after intragastric administration and 14.5% of the intraperitoneally administered dose was detected within 1 hour of administration. Further, from 6 to 72 hours after treatment, blood levels were similar regardless of the route of administration and declined steadily to 2.5% of the dose after 72 hours Norred 1990) .
Pigs. An average plasma concentration of 464 ng CPA/ml was detected in 3 adult Piétran crossbred pigs fed a nishing diet containing 10 ppm CPA over a 6 day period (Byrem et al. 1999b ). Both longissimus and semitendinosus muscles showed similar CPA concentrations as plasma.
Distribution
Rats. Norred et al. (1985) (see above) described the concentration of labeled material in organs and tissues at the time of peak blood levels (i.e., 6 hours for intragastric administration) and 1 hour for intraperitoneal administration. Lung, heart, kidney, liver, and skeletal muscle had the greatest amounts of labeled material, but no tissue exceeded the speci c activity found in blood. The organs and tissues with the lowest speci c activity in both intragastric and intraperitoneally dosed rats were salivary gland, thyroid, testis, adrenal gland, spleen, brain, eye, fat, and skin (no ranking was given).
In the livers of rats dosed intraperitoneally, rapid accumulation of label occurred during the 1st hour, but then the levels declined to less than those in the rats dosed intragastrically. By 72 hours, the livers of rats treated by either route contained less than 1% of the dose of radioactivity.
The largest percentage of administered radioactivity at each time interval was in skeletal muscle. The label appeared more rapidly in the muscle of the rats dosed intraperitoneally, but from 6 to 72 hours, the percentage of the dose accounted for (i.e., amount of remaining label) was similar for both routes of administration and was linear with time. During the rst 12 post-dose hours, 45 to 50% of the radiolabeled dose (as CPA or CPA metabolites) distributed to muscle (muscle accounts for approximately 50% of a rats body weight) Norred 1990) . The localization in skeletal muscle may explain some of the clinical signs of toxicity such as weakness, incoordination, and lethargy as a result of a direct action of CPA on muscle tissue.
Pigs. The plasma kinetics of CPA in four market-weight pigs, each receiving a single intravenous administration of 20 mg CPA, was best characterized in a three-compartment model with a rapid distribution, a large volume of distribution (49 L), and a slow elimination (t 1/ 2 = 24 hours) (Byrem et al. 1999b ). Plasma and muscle CPA concentrations in pigs were similar following 6 days ad libitum consumption of diet containing 10 ppm CPA, thereby supporting their nding of a large volume of distribution-roughly equivalent to the total body water content (Byrem et al. 1999b) .
Excretion
Rats. A signi cant portion of administered radioactivity was recovered from Sprague-Dawley rats with recovery of 86.9 § 10.1% and 95 § 10.9% for the intraperitoneal and intragastric routes, respectively. Regardless of the route of administration, CPA was rapidly eliminated from the body with a biological half-life of 33 § 12 hours for intraperitoneal administration and 43 § 25 hours for intragastric administration. Rats, treated intraperitoneally, excreted 23% of the dose in urine and 37% in feces within 72 hours. No radioactivity was eliminated via expired air. After intragastric administration, 17% was eliminated in urine and 48% in feces over the same time period. Total radioactivity in the gastrointestinal tract decreased rapidly for the rst 12 hours after intragastric dosing and then gradually declined to 3% of the dose by 72 hours. After intraperitoneal treatment, 5% of the dose of radioactivity appeared in the gastrointestinal tract within 1 hour; this increased to 13% by 12 hours and remained at 5 to 9% of the dose for the next 60 hours Norred 1990) . Pigs. Pharmacokinetic studies on market weight pigs demonstrated a long half-life (t 1/ 2 = 24 hours) following a single intravenous administration of 20 mg CPA (Byrem et al. 1999b ). The route of elimination of CPA was not studied by the authors, although an enterohepatic circulation was speculated based on previous studies reported by Norred et al. (1985) .
Toxicological Studies Acute Toxicity Studies
A summary table of acute toxicity studies is provided in Table 3 . Clinical ndings in mammals were similar in all studies with reports of ptosis, hypokinesia, ataxia, hypothermia, action tremor, convulsions, and cessation of food and water intake. Relevant ndings in mammals are described below.
The most detailed and oft-cited observations were made by Purchase (1971) , who orally dosed groups of ve male and ve female (Wistar-derived) rats with CPA (dissolved in l N sodium bicarbonate). Males received 30, 36.7, 45, and 55 mg CPA/kg and females received 30, 36.7, 45, 55, 67.5, and 82 .6 mg CPA/kg. A control group of each sex was dosed with 10 ml/kg of 1 N sodium bicarbonate. All survivors were killed at 10 days and organs were taken for microscopic examination. The oral LD 50 in males was 36 mg CPA/kg (31.7-40.9 mg CPA/kg) and for females, 63 mg CPA/kg (52.3-68.8 mg CPA/kg). The oral administration of CPA produced different reactions in the animals than did intraperitoneal injections, most likely as the result of poor absorption in the acidic environment of the stomach as compared to the more neutral environment of the peritoneum. All rats that died were prostrate for several hours before death, but no muscle spasm was observed. Curiously, all mortalities in female rats occurred within 36 hours of dosing, whereas all mortalities in male rats occurred between the 2nd and 6th day. Macroscopic examination was generally unremarkable albeit some degeneration was noted in the kidneys or liver in rats exposed to high doses of CPA. Microscopic changes of those rats dying within 36 hours were distinct from those dying after 4 to 6 days, suggesting a sex-linked difference in response to CPA (Purchase 1971) .
Microscopic examination of the females (all of whom died within 36 hours of dosing) revealed degeneration of bile duct cells, which was progressive with dose and occlusion of the ducts was at the highest doses. In kidneys, necrosis was seen in the lining cells of the tubules at the corticomedullary junction and the outer zone of the medulla. At higher doses, there was cell pyknosis and in adjacent cells, the cells were swollen and blocked the lumen, as seen in the bile duct. The islets of Langerhans also showed degenerative changes and pancreatic duct cell changes were similar to those seen in the bile duct. Some splenic lymphocytes were necrotic, but the necrosis and atrophy seen in the male rats was not observed. At the highest doses, individual cells in the adrenal cortex were necrotic. No marked changes were seen in the myocardium (Purchase 1971) .
Microscopic examination of the males (all of whom died 4-6 days post dose) revealed lesions in the liver similar to those seen in females. In two rats, ne fatty vacuolation of the hepatocytes was seen. The kidney lesions were milder, with necrosis of the tubules at the corticomedullary junction predominating. The pancreatic changes were similar, but not as severe. The spleen, particularly at higher doses, was atrophied. The capsule was irregularly folded and the white and red pulp less densely packed than in controls. Some necrotic lymphocytes were seen. At higher doses, hemorrhage into the necrotic areas was present. Extensive hyaline degeneration of the myocardium was seen in these rats, associated with occasional coagulative necrosis of myocardial bers and hemorrhage into the small necrotic areas (Purchase 1971) .
Among the survivors killed at 10 days (males and females), changes were observed in all organs similar to those seen above. The variation in severity was marked with some rats at lower doses showing no abnormalities and others at higher doses showing distinct hepatic and pancreatic lesions. In general, the renal lesions were less pronounced than those in other organs (Purchase 1971) .
In an expanded study to determine the pathogenesis of the lesions described above, Purchase (1971) dosed 12 male rats per os with 50 mg CPA/kg and 6 controls with an equivalent volume of sodium bicarbonate solution. One control and two treated animals were sacri ced at 8, 16, and 24 hours and 4 and 8 days post dosing. No macroscopic changes to the major organs were noted in these animals. The earliest microscopic changes observed were in the liver, with single cell necrosis of hepatocytes and bile duct cell changes at 8 hours. The severity of the liver lesions was maximum at 24 hours with swollen bile duct cells obstructing the lumens. Hepatic damage was less severe at 48 hours and in animals sacri ced 96 and 192 hours post dosing, no hepatocytic abnormalities were observed, although some swelling of bile duct nuclei was still evident (Purchase 1971) . Renal tubular cells of the medulla showed degenerative changes at 8 hours and between 16 and 192 hours, the tubular cells in the medulla were pyknotic and only a few had dilated, clear-centered nuclei. The vacuolation of the cytoplasm in tubular cells was most marked between 48 and 96 hours. Pancreatic changes were rst observed at 16 hours and by 96 hours, the ductal changes had advanced with some apparent necrosis. The islet lesions were still present at 192 hours. No changes were observed in the acinar cells at 192 hours, although some single cell necrosis was present at 96 hours. In the parotid and submandibular salivary glands, changes were observed in the ducts at 48 and 92 hours; duct cell nuclei were swollen, but there was no obstruction of the lumen. Necrosis of acinar cells was present at 48 hours. Changes in lymph nodes and spleen were limited. No frank atrophy as seen in the LD 50 group was noted. At 24 and 48 hours, hyaline degeneration of the myocardium was present. At the same time, hyaline degeneration in skeletal muscle was observed. No abnormalities were observed in the thyroid or adrenal glands (Purchase 1971) .
Following intraperitoneal administration of the toxin, Purchase (1971) noted the rats receiving 8 mg/kg or more died within 2 hours, showing neurologic symptomology. Beginning at about 5 minutes, the rats were disinclined to move, became ataxic and were dif cult to handle. At varying intervals from 10 to 30 minutes later, the rats became immobile and eventually died in extensor spasm and exhibited cyanotic mucous membranes. The animals in groups receiving 2.5 and 4.5 mg/kg died 1 to 3 days after dosing and those receiving lower doses (to 0.8 mg/kg) recovered and survived until sacri ce on the 10th day. The pathology of these rats was not studied (Purchase 1971) . Rao and Husain (1985) injected mice intraperitoneally with 1 mg/g of a chloroform extract (found to contain cyclopiazonic acid) from a sample of kodo millet (Paspalum scrobiculatum) reported to cause kodua poisoning in humans. The mice showed typical symptoms of kodua poisoning, i.e., immediately after injection, the animals became depressed and lost their mobility. The animals moved to the corners of the cages and were reluctant to move even on provocation. The symptoms lasted for about 7 hours, after which the mice recovered. Similar crude extracts of the fungi grown on broth resulted in the animals developing respiratory stress followed by convulsions and death within 30 minutes (Rao and Husain 1985) .
In a further exploration of the neurogenic effector mechanisms of CPA, (using CPA isolated from A. avus culture and dissolved in 1 M NaHCO3) administered CPA (10 mg/kg) intraperitoneally to mice at 30 minutes and 24 hours. The total volume administered was 10 ml/kg. The control groups received 10 ml/kg of sodium bicarbonate intraperitoneally. CPA was reported to increase the hindbrain metabolites, homovanillic acid and dihydroxyphenylaceti c acid, but 
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deceased 5-hydroxyindolaceti c acid when measured 30 minutes after administration. However, no change was observed at 24 hours. Serotonin and norepinephrine were unchanged by CPA, but the levels of dopamine were increased, suggesting that the neurogenic actions of CPA were not due to the depletion of amines. CPA may, however, be involved with both dopaminergic and serotonergic systems, because it induced a marked increase in dopamine and a decrease in 5-hydroxyindolacetic acid. With approximately equipotent doses of CPA, chlorpromazine and reserpine did not cause equivalent hypothermia, catalepsy, or changes in neurotransmitter levels . New Zealand white rabbits, administered 10 mg CPA/kg body weight intraperitoneally, initially experienced tachycardia, tachypnea, and sedation with an activated electrocardiogram (EEG). Of three rabbits given 10 mg CPA/kg, one died, and in this rabbit, slow delta waves were seen just before and during a brief period with clonic leg movements. Also in this animal, death was accompanied by tonic extension of the hind legs, respiratory arrest, and cardiac brillation, although epileptiform EEG was not seen at any time. The unexpected EEG activation with sedation in rabbits treated with CPA was similar to the effect of reserpine on EEG .
Subchronic Toxicity Studies
A considerable number of multiple-dose studies have been reported using a variety of test materials and a range of duration from three to 120 days. Unfortunately, not all studies were equally meritorious, as some suffered from serious aws in study design, animal husbandry, or consistency of results. The most relevant reports on mammals are described below and summarized in Table 4 in addition to studies on poultry and sh.
Multiple dose studies with molds or crude extracts
Some studies were conducted using feedstuffs contaminated with mold or crude extracts of feedstuffs or mold itself. For example, a total of 228 isolates from 26 species of Aspergillus and 28 species of Penicillium plus isolates from other species were grown in maize meal (3 strains of P. cyclopium Westling, 5 strains of A. versicolor Tirahoschi, and 10 strains of A. avus were used). All of the strains were capable of producing CPA (Cole and Cox 1981) . Austwick et al. (1979) noted similarities between pathology of "Balkan nephropathy" and reports of mold toxicity. Barnes et al. (1977) had taken samples of molds in Bulgaria where Balkan nephropathy is endemic. The molds were grown in culture, homogenates made of the cultures, and the homogenates fed to rats. One culture, Penicillium verrucosum var. cyclopium, was found to produce renal lesions in male Lac P rats fed an extract of the mold 5 days per week for 4 weeks. The lesions, con ned to the lower reaches of the proximal convoluted tubules (pars recta and junctional zone), closely resembled the tubular changes in patients with Balkan nephropathy. Austwick et al. (1979) took similar samples and fed rats over a longer period. They noted microscopic lesions were con ned to the corticomedullary junc-tional zone (more precisely to the epithelial cells of the third (P 3 ) segment of the pars recta) of the proximal tubules. Pronounced degeneration and necrosis occurred, characteristically with nuclear enlargement and frequent binucleate cells. After 6 months, the rats remained healthy but a pale zone had become visible in the outer stripe of the renal medulla of those sacri ced. Dilated tubules with extensive epithelial cell loss, pronounced karyomegaly, and multinucleate cells were also seen. Electron microscopy, performed at sacri ce after 1 month of feeding, revealed characteristic changes in the tubular epithelial cells. These changes consisted of degeneration, focal loss of the brush border, arrested mitoses, and multinucleated cells in which the nuclei were often of unequal size and apparent composition and had segregated nucleoli (Austwick et al. 1979) . The association of Balkan nephropathy and CPA is disputed by Ciegler (1980) , who insisted Balkan nephropathy should be attributed to ochratoxin. The association of Balkan nephropathy with ochratoxin is discussed by the International Agency for Research on Cancer (IARC 1983) .
Multiple dose studies with cyclopiazonic acid
Rats. Norred et al. (1984) administered CPA per os 0, 0.2, 2, 4, or 8 mg CPA (dissolved in 1 N sodium bicarbonate)/kg on 4 successive days to male Sprague-Dawley rats and examined them for histological and liver enzyme changes. They found that rats that received the highest dose of CPA were dead or moribund by day 5 and the livers had diffusely distributed areas of coagulative necrosis. Nuclei in the center of each damaged area were fragmented, whereas those nuclei more peripherally located were pyknotic or were undergoing karyorrhexis. These rats also lost weight, had larger livers, and had reduced cytochrome P450 values compared to rats in the other treatment groups. Glutathione S-transferase, serum ornithine carbamoyltransferase, and microsomal and cytosolic protein values were not affected by CPA. Morrissey et al. (1985) examined the effects of short-term CPA administration to male Sprague-Dawley rats. CPA was administered per os on 4 consecutive days at 0, 0.2, 2.0, 4.0, and 8.0 mg/kg with control animals receiving 2 ml of 1 N sodium bicarbonate/kg. Clinical signs of toxicity were observed only in the two highest CPA dose groups. Rats in the highest-dose group exhibited abnormal behavior, diarrhea, and other signs of toxicity after several days of dosing. Most animals were moribund before the last scheduled dose was administered and one rat died. Food consumption was progressively less each day in the highestdosed group resulting in signi cantly reduced weight compared to control animals. The liver and spleen were more affected than other organs in the two highest-dose groups. Livers contained diffuse pyknotic nuclei and, in some high-dose rats, focal areas of coagulative necrosis. These animals also had elevated aspartate and alanine aminotransferase activities, decreased cytochrome P450 concentration, but glutathione S-transferase activity remained unchanged. Spleens were hemorrhagic and white pulp contained necrotic lymphocytes. White cell counts were decreased in a dose-related manner in the two highest-dose groups. The gastrointestinal tract of high-dose rats contained cells with pyknotic nuclei and sites of necrosis were observed in the stomach, but these lesions were not seen in all animals and were generally mild. Pathological changes in conjunction with decreased feed and water intake probably contributed to the general deterioration of high dose rats that eventually resulted in death .
Van Rensburg (1984) gavaged male and female Wistar rats with 0, 12, or 21 mg/kg CPA ( >99% pure CPA in 1 N sodium baricarbonate), once weekly for 14 weeks. Four animals per sex of each of the treated groups and two animals per sex of the control were sacri ced at the conclusion of 1, 2, 5, 9, and 14 weeks of treatment. Four high-dose male rats died within a few days of each other during week 4. Also, high-dose male rats experienced a statistically signi cant, but transient, growth depression, although they recovered by week 4. There were no other changes in other treated or control animals. No gross pathological changes were noted in any animals. Histopathological changes included mild cellular degenerative changes in the myocardium and characteristic nuclear ballooning, especially of ductal epithelial cells. Change was minimal in the liver, but the kidneys exhibited tubular-cell changes at the corticomedullary junction, including nuclear ballooning, bizarre shapes, and margination of chromatin. Mild vacuolar-like changes in glomerular endothelial cell nuclei were occasionally present. In the spleen, mild atrophy was reported with fewer and smaller lymphocytes in the germinal centers and fewer erythrocytes in the red pulp. In the later stages in the experiment, high-dose rats showed a tendency to develop nuclear vacuoles in lymphocytes, reticuloendothelial cells, and macrophages. In the salivary glands, serous and ductule cells became swollen and exhibited nuclear changes early on in the experiment; later, mitotic gures were evident and ultimately tubules appeared to have pseudostrati ed epithelium containing swollen cells with peripherally arranged chromatin. In the pancreas, some changes were noted in the islet of Langerhans and nuclei of small ducts were invariably swollen with clear centers, but the larger ducts were not consistently affected. The changes were only weakly related to dose level, sex, and the number of doses given. The ndings also suggested that cycl-opiazonic acid is probably a metabolic inhibitor requiring high doses to achieve toxicity (Van Rensburg 1984) .
In a study reported by Voss et al. (1990) , CPA was isolated from Penicillium griseofulvum, puri ed to a level¸95% and administered in 1 N sodium bicarbonate (2 mg/ml) at doses of 0, 0.2, 0.6, 2.0, or 4.0 mg CPA/kg/day, daily for 13 weeks to Sprague-Dawley rats in ve groups of 12 rats/group. Clinical laboratory studies were conducted on fasted rats after 7 and 13 weeks. Hematological parameters were checked in addition to alkaline phosphatase, alanine aminotransferase, aspartate aminotransferase, lactate dehydrogenase , total protein, triglyceride, bilirubin, glucose, blood urea nitrogen (BUN), and creatinine concentration. CPK and cholesterol concentration were measured after 13 weeks only. Gross and microscopic pathology were conducted. Two gavage-induced deaths were reported but there were no other effects on the animals' appearance or behavior; body weight and food consumption were comparable between groups. There was a slight, but dose-related increase in creatinine concentration after 7 and 13 weeks in males and females at 2 and 4 mg/kg/day. The authors stated there were no other clinical ndings and did not present any additional data. The absolute and relative weights of the adrenals were increased in the 4.0 mg/kg group and absolute and relative kidney weights were decreased at 2 and 4 mg/kg/day. No gross abnormalities were present except in the gastric lining in ve high-dose animals and one animal at 2 mg/kg. The histopathological effects were con ned to the stomach and consisted of acute in ammation of the lamina propria and submucosa of the glandular epithelium in the majority of animals in the 0.6, 2, and 4 mg/kg dose groups. The endoplasmic reticulum of high-dose animals was slightly disorganized with loss of cisternal pattern and ribosomal detachment; no ultrastructural abnormalities were found in rats given 2 mg/kg/day. Voss et al. (1990) concluded that 4.0 mg/kg/day was a no-observable-effect level (NOEL) and the mucosal effects were secondary to gavage. There was speculation that the creatinine increase was secondary to CPA accumulation in the muscle.
In a follow-up study, Voss et al. (1990) acclimated male Sprague-Dawley rats and divided them into two groups of ve animals each. The animals were given 1 N sodium bicarbonate buffer or buffer containing 8.0 mg CPA/kg/day for 4 days. Concentration of CPA in the dosing solution was 2.0 mg/ml. Again, there was a departure from the usual pathogenesis of CPA intoxication with few clinical signs of toxicity and only a slight, transient weight loss in one CPA-treated animal. Weight gain and food consumption in the other four animals were comparable to controls. Voss et al. (1990) remarked that these results were at variance with previous studies in which the same dose was administered and in which morbidity, marked weight loss, and histopathological effects typical of CPA exposure were found. The disparity has been attributed to a difference in batches of CPA ). Hill et al. (1986) administered CPA intraperitoneally to Sprague-Dawley rats at daily doses of 0.1, 1, and 5 mg CPA/kg for 28 days. Each group consisted of three animals of each sex. The controls were given 0.5 ml of 1 N sodium bicarbonate intraperitoneally once daily for 28 days. One rat in the high-dose group died on day 28 of diarrhea, dehydration, and weakness. At the high-dose, there was a signi cant decrease in weight gain and the livers appeared rounded at the edges when compared with control and low doses. Group mean liver, kidney, and spleen weights did not differ between groups. Total protein, albumin, packed cell volume, and hemoglobin were not altered. The 1 and 5 mg/kg dose groups had higher neutrophil counts and lower mean eosinophil and lymphocyte counts than did the controls. Bone marrow and cell ratios were normal. At 0.1 or 1 mg CPA/kg, there was a reduction in antibody (Ab) titer against sheep red blood cell (sRBC) 5 days after injection. The 0.1 mg/kg group also had a reduction in antibody (Ab) titer 7 days after injection. By day 14, the treated groups had a significantly higher Ab titer than did the control group. Microscopic lesions were noted in all dose groups, but the degree and extent were not proportional to the dose. The lesions were generally limited to the liver and kidneys. They were characterized by vacuolated to granular hepatocyte cytoplasm and dilated renal convoluted tubules, many having pyknotic nuclei and scattered hyaline casts. Splenic destruction or depletion of lymphocytes were not observed (Hill et al. 1986 ).
In order to determine the histological effects of CPA on skeletal muscle, male HSD:Sprague-Dawley BR rats were dosed intragastrically for 4 consecutive days with 8 mg CPA/kg/day. The control rats received only the vehicle (1 N sodium bicarbonate). The animals were sacri ced on day 5. Degenerative lesions in skeletal muscle were reported. Scattered muscle bers were eosinophilic and in cross-section these bers had lost contact with other cells within the bundle. Cross-striations were preserved. Nuclei of the affected bers varied in shape from elongated to almost round and stained hyperchromatically. Most of these nuclei maintained a peripheral position . Hinton et al. (1985) con ned their tissue examination to the liver. Groups of male Sprague-Dawley rats (eight animals per group) were dosed per os for 4 consecutive days with 0, 0.2, 2.0, 4.0, or 8.0 mg CPA (in 1 M sodium bicarbonate)/kg/day and were killed on the 5th day. Control rats received 2 ml 1.0 M sodium bicarbonate/kg (all animals received the same volume per kg body weight). Sections of liver were taken for electron microscopic examination. They reported that rats dosed with 8.0 mg CPA/kg died prior to the xation of tissues and were not included in the study. Some rats receiving 4.0 mg/kg/day exhibited nonspeci c toxic signs, such as rough fur coats and sunken eyes, within 24 hours of dosing. No signs of toxicity were noted at 0.2 or 2.0 mg/kg. Dilation of the rough endoplasmic reticulum was observed in all hepatocytes examined from the 2.0 and 4.0 mg/kg dose groups and in about 25% of liver cells from (all of the animals in) the 0.2 mg CPA/kg/day group; the biological signi cance of this nding is uncertain at the low dose. Vesiculation of the rough endoplasmic reticulum also occurred in these groups and degree of vesiculation was dose dependent. Control sections exhibited neither of these characteristics. No proliferation of smooth endoplasmic reticulum (SER) or blockage of bile canaliculi was observed in any group. Mitochondria from rats dosed with 2.0 or 4.0 mg CPA/kg/day were swollen and the swelling was more pronounced in mitochondria from the high-dose rats. Mitochondrial membranes were intact in all sections examined. Lysing cells were observed only at the 4.0 mg/kg dose (Hinton et al. 1985) . A no-adverse-effect level was likely achieved at the 0.2 mg/kg dose.
Six-week-old Wistar rats were administered 10 l g of toxin (volume of 0.4 ml) (approximately 2 mg CPA/kg/day) for 60 days to determine the effect on liver enzyme synthesis. Four hexoki-nase isoenzymes were fractionated by a modi ed method using two DEAE-cellulose columns. The data indicated the level of glucokinase in the fraction with high K M was lowered significantly in the toxin administered rat liver, but the K M value (1.25 £ 10 ¡ 3 M) and its af nity for glucose and ATP remained unaltered. The authors concluded that the decrease in enzyme concentration in test rat liver may have been due to decreased synthesis of the isoenzyme during cyclopiazonic acid toxicosis (Rathinavelu et al. 1986 ).
Guinea pigs. Penden (1989) , using male guinea pigs, administered 2 mg CPA/capsule (approximately 4 mg CPA/kg/day) for up to 4 days. Serial sacri ces were carried out with a sacrice at 8 and 16 hours following a single dose of CPA and the remainder of sacri ces taking place 16 hours after the animals had received a second, third, or fourth dose of CPA. The author noted rough hair coats in the animals given two doses and more severe clinical signs were seen in the animals given three or four doses. Severely affected guinea pigs had slow, weak, and irregular leg movements when placed on their sides and righting re ex was impaired. No trembling was noted. Body weight was diminished. Four-dose CPA animals had elevated creatinine phosphokinase, serum phosphate, and BUN, but statistical inferences could not be made due to the small number of animals. Aspartate aminotransferase and alanine aminotransferase appeared to be in ux, but the changes were not proportional to the duration of dosing.
Histological changes in muscle were proportionate to duration of dosing and included mild changes in the gastrocnemius, vastus lateralis, and biceps femoris in guinea pigs dosed for 3 days. In those dosed for 4 days, there were pronounced changes in two out of ve animals, with increased numbers of necrotic bers, separation of bers by edema, and increased numbers of in ammatory cells. There was also an increase in the number of round, swollen, deeply eosinophilic, hyaline bers compared to controls. Frozen sections stained with Gomori's trichrome had changes similar to that seen with hematoxylin and eosin. Affected myo bers varied in appearance from a swollen, dense, hyaline, homogeneous appearance to bers with hyaline bands and whorls often separated by more lucent to granular cytoplasm. Necrotic and degenerate bers stained with nicotinamide adenine dinucleotide-tetrazolium reductase contained large, focal, dense aggregates of tetrazolium reductase activity (formazan granules) (Penden 1989) .
Electron microscopy of skeletal muscle revealed few and nonspeci c changes in animals receiving one or two doses, aside from swollen mitochondria and an increase in lipid vacuoles within individual bers. At 3 days of dosing there were swollen mitochondria, dilatation of the sarcoplasmic reticulum, and segmental necrosis of myo bers. At four doses, there were similar but more severe and numerous lesions in myo bers. There was an abrupt transition from normal to severely degenerate or necrotic bers (Penden 1989) .
Three-and four-day guinea pigs had mild to moderate hepatocellular vacuolation. Vacuolated hepatocytes were present around the central vein and portal areas, although more numerous in the former. Testes, adrenal gland, mesenteric lymph nodes, spleen, kidney, and brain were normal. Lesions in the gastrointestinal (GI) tract were restricted to the lower tract and although diarrhea was seen in three-and four-dose animals, no changes were evident. Lungs of treated and control animals showed signs of disease (Penden 1989) . Richard et al. (1986) divided white female guinea pigs weighing 450 to 500 g into groups of ve animals each to receive daily doses of 0.0, 0.00625, 0.0125, 0.025, 0.05, 0.1, 0.2, 0.4, 0.8, 1.6, or 1.95 mg CPA/gelatin capsule for 30 days. Mortalities (2/5) occurred in groups given 1.6 and 1.95 mg CPA/day. By the 3rd day, the high dose animals developed a roughened hair coat and arched back and appeared to be in pain because they squealed excessively when forced to move. On postmortem examination, guinea pigs given 0.8 mg CPA/day had congested livers, whereas those given 1.6 mg/day had tan livers with prominent lobules. One guinea pig in this group had a stomach ulcer, although the severity of alimentary ulceration did not appear to approach that reported by Nuehring et al. (1985) . Guinea pigs administered greater doses of CPA had mottled to yellow livers with prominent lobules, enlarged gall bladders, and stomach hemorrhages, and some had blood or dark uid in the ileum and colon. Histopathological examination showed animals at 0.2, 0.4, and 0.8 mg CPA/day having minor nonspeci c lesions, including peribronchiolar and perivascular cuf ng of lymphocytes. All groups had an occasional microfocus of hepatocellular necrosis and accompanying mononuclear in ammatory cells. Animals at 1.6 mg CPA/day that died had moderate to severe hepatocellular vacuolar degeneration, most prominently in the centrolobular areas. Animals killed on the same day had similar, but less severe, lesions of hepatocellular vacuolation. Animals dosed with 1.95 mg/day had the most pronounced lesions. The two animals that died had moderate to severe hepatocellular vacuolar degeneration; mild, focal super cial necrosis of gastric mucosa; and in ltration of neutrophils in the deeper gastric mucosa. A slight increase in total protein and albumin were seen at 1.6 and 1.95 mg/day. Aspartate aminotransferase, alanine aminotransferase, and sorbitol dehydrogenase (SDH) concentrations were increased at 1.6 and 1.95 mg/day. There were no changes in serum alkaline phosphatase (SAP) concentrations. The total serum bilirubin concentration was slightly elevated with increasing doses of CPA. No effects on weight gain were noted in survivors. Based on the authors descriptions, a NOEL is estimated to be 0.4 mg CPA/day (approx. 1.0 mg/kg) (Richard et al. 1986 ).
Eight guinea pigs per group were dosed orally (by capsule) with CPA (2.2 mg/kg) or a atoxin (0.045 mg B 1 /kg) singly or in combination (nine animals) for 21 days. None of the animals receiving either CPA or a atoxin alone died, whereas the groups receiving both had 6/9 death. There was a signi cant difference in CPA and control body weight at day 11, but not by day 21. The livers on gross examination were light grayish in color and had large gall bladders. Histopathologically, there was some vacuolation in centrilobular hepatocytes. Reaction to intracutaneous PHA or delayed cutaneous hypersensitivity was not decreased in CPA treated animals versus controls. In vitro culture of lymphocytes and response to phytohemagglutinin (PHA) with CPA had no effect. There was no change from control in ability to produce classical complement or humoral antibodies (Pier et al. 1989) .
Pigs. Five-to 6-week-old crossbred pigs weighing 5 to 14 kg were divided into groups of four animals and given CPA in gelatin capsules at doses of 0.01, 0.1, 1.0, or 10 mg/kg for 14 days. There were clinical signs of toxicity by day 7 in pigs given 10 mg/kg that included weakness, inactivity, anorexia, rough hair coats, and reduced body weights (Lomax, Cole, and Dorner 1984) . Diarrhea developed by the 2nd week. The pigs receiving 1 mg/kg also exhibited rough hair coats and were moderately inactive during the 2nd week of the experiment. At necropsy, lesions were observed only in pigs given 1.0 and 10 mg/kg. Leukocytosis was seen in the high-dose pigs, but hematocrit, plasma protein, hemoglobin, serum calcium, phosphorus, magnesium, total protein, albumin, BUN, alkaline phosphatase, aspartate aminotransferase, and c -glutamyltransferase did not differ from controls. Organ weights of treated and control animals did not differ. Grossly observable lesions on postmortem examination included gastric ulcers, mucosal hyperemia, and hemorrhage throughout the small and large intestine in pigs given 10 mg/kg. The pigs also had yellow, brinonecrotic material in the lumen of the small intestine, and pale livers. One pig given 1.0 mg/kg had gastric ulceration. Microscopic ndings in pigs given 10 mg/kg included necrotizing gastroenteritis, focal hepatocellular necrosis, hepatic peripheral lobular fatty changes, and focal renal tubular nephrosis with focal suppurative tubulointerstitial nephritis. Pigs given 1.0 mg/kg had necrotizing gastritis and villous blunting in the jejunum and ileum. A NOEL was offered at between 0.01 and 0.1 mg/kg because lesions were observed in the gastrointestinal tract at levels as low as 0.1 mg/kg (Lomax, Cole, and Dorner 1984) .
The actual NOEL is likely higher than that offered because (1) the only gross lesion in the 1.0 mg/kg group was seen in a single animal (one of eight) in two different trials (four pigs per group each trial), (2) the microscopic pathology was found in only two of eight pigs at the 1.0 mg/kg level and in two of eight pigs at the 0.1 mg/kg dose level, and (3) the anatomy of the porcine digestive tract in the area of the observations would tend to predispose to such a diagnosis. Therefore, although CPA may have been contributory to the gross and microscopic pathology in the high-dose animals (10 mg/kg/day), the investigators may have overestimated the effects at the lower dose levels. Based on these considerations, we would estimate the NOEL in this study to be 1.0 mg/kg/day. Pigs, as well as humans, can carry a unique genetic mutation of the skeletal muscle calcium channel leading to the onset of malignant hyperthermia. This mutation is manifested by a slow and unregulated calcium ux into the cellular cytoplasm. At slaughter, pigs with the malignant hyperthermia trait can produce meat termed pale, soft, and exudative (PSE), which is a descriptive term of the low pork quality (Byrem et al. 1999a ). Due to the similar calcium effects of CPA in muscle tissue, Byrem et al. (1999a) examined the effects of CPA on the development of PSE pork. Market-weight pigs were fed 0.1 to 50 mg CPA/kg diet for 10 days prior to slaughter and excised meat samples were examined for quality and the presence of CPA. Longissimus muscle CPA concentration was 109 to 2498 l g/kg in pigs administered 2.5 to 50 mg CPA/kg feed (Byrem et al. 1999a) . CPA had little effect on feed intake, average daily weight gain, muscle pH following slaughter, or on the development of PSE meat (Byrem et al. 1999a ). These results were the same between normal pigs and those which were heterozygous or homozygous for malignant hyperthermia (Byrem et al. 1999a ). Byrem et al. concluded that "The minimal effects of cyclopiazonic acid on live animal performance and meat quality traits in the present study do not support concerns that its natural presence in agricultural commodities is an important threat to the health of market weight pigs . . . " (Byrem et al. 1999a) .
Dogs. Nuehring et al. (1985) dosed four groups of mixedbreed dogs with CPA in gelatin capsules for 90 days at 0.05, 0.25, 0.5, and 1.0 mg CPA/kg; a fth group was used as a control. All dogs administered the 0.5 and 1.0 mg/kg dosages and one dog given the 0.25 mg/kg dosage died or were humanely killed before the scheduled termination of the study. Clinical signs of intoxication appeared 2 to 44 days after dosing started and consisted of anorexia and, in 1 to 2 days, vomiting, diarrhea, pyrexia, dehydration, weight loss, and central nervous system (CNS) depression. Grossly, the entire alimentary tract (including soft palate, which had crateriform lesions) had diffuse hyperemia with focal areas of hemorrhage and ulceration. Other lesions were renal infarcts, necrotizing epididymitis, and ulcerative dermatitis. Dose-related gross lesions were most often observed in the alimentary tract and kidneys of dogs in the 0.25, 0.5, and 1.0 mg/kg dosage groups. Microscopic lesions included ulceration, necrosis, vasculitis, lymphoid necrosis, and karyomegaly in several organs and increased mitotic activity in intestinal crypt epithelium. Ulcerative and necrotic lesions were usually associated with vascular lesions. Clinical pathological changes were leukocytosis, neutrophilia, lymphopenia, and monocytosis, although the increases were not proportional to dose. There were also increases in serum alkaline phosphatase activity at the 0.25, 0.5, and 1.0 mg/kg dose levels, but as with the formed elements of the blood, the increases were not proportional to dose, because the 0.5 mg/kg level was greater than the other doses. There were no signi cant changes in packed cell volume, platelets, hemoglobin, total protein, BUN, albumin, total and direct bilirubin, c -glutamyltransferase, aspartate aminotransferase, and alanine aminotransferase. One female in the 0.25 mg/kg group whelped on day 28. The pups were killed shortly after birth and no gross abnormalities were observed. Non-dose-related ndings observed in these dogs were due to parasitism and infectious disease (purulent bronchopneumonia in two dogs) and a brosarcoma in one dog. Dogs at the high dose had grossly visible ascarid larvae granulomas in the kidney, two dogs were found pregnant during the study, and two dogs were found to have been spayed (Nuehring et al. 1985) .
We believe the ndings of this dog study by Nuehring et al. (1985) to be inconclusive because (1) the small number of animals studied precluded statistical analysis of the data, and (2) the health status of the animals was clearly compromised at the outset of the study. In support of the un t nature of these animals as test subjects, the authors indicate (1) the animals were of unknown lineage and were "strays" with unknown medical histories, and (2) they were subject to a number of intercurrent pathological conditions during the study (pneumonia, neoplasia, and parasitic infestation). A close examination of the data reveals that (1) the white cell counts were at the upper most of the range or exceeded the range for all groups at study termination (Siegmund 1973 ); (2) most of the elevated parameters, including neutrophil count, segmented neutrophils, bands, monocytes, and serum alkaline phosphatase, were higher in the 0.5 mg/kg animals than in the 1.0 mg/kg animals; and (3) if the alimentary tract ulcers and erosions were as extensive as described, one could reasonably expect a proportionate decrease in packed cell volume, but the investigators indicated there were no differences in hematocrit. On the basis of the evidence presented, the study should be held inconclusive and in distinction to other studies presented in this review which, in general, were executed with an adequate number of animals of known husbandry, were of sound physiological status (at initiation of treatment), reasonably free of intercurrent disease while on study, and whose post-treatment ndings were reasonably congruent.
Monkeys. In a nonterminal pilot study with a single monkey, Jaskiewicz et al. (1988) dosed a female vervet monkey with 1 mg CPA/kg per day ve times per week in gelatine intragastrically at the commencement. Thereafter, the dose was doubled every 3rd day to achieve 60 mg/kg/day. Duration of the study was 16 weeks. No grossly observable effects were noted.
Two male and three female monkeys (including the one used in the acute toxicity experiment, see above) were fed 20 mg CPA/kg intragastrically in gelatin. One male and one female served as controls. On the 5th day skeletal muscle was biopsied. Two males and one female monkey were sacri ced after 60 days of treatment. After 120 days of treatment, biopsies were taken from the liver, kidney, pancreas, stomach, large and small intestine, and from skeletal muscle from the two remaining monkeys. During the course of the study sporadic emesis was recorded. Mild and transient increases in aspartate aminotransferase, alanine aminotransferase, BUN, and creatinine levels in plasma of females were observed at the 9th week. The males had a mild plasma lactate dehydrogenase activity increase during the 2nd week of treatment. One monkey developed cardiac arrhythmia under ketamine anesthesia and died at the end of the 2nd month. Microscopic lesions were mild and irregular. They involved epithelial cells of the biliary and pancreatic ducts.
Lesions were also found in the renal medullary tubules, protein casts. There was also minute tubular atrophy. Myocardial lesions were present in two treated animals. Ultrastructural changes occurred in the small vessels, particularly in the capillaries of the heart and kidneys with thickening of the endothelium. Myocytes revealed focal lysis of myo brillae, mitochondrial accumulation, and lysosome formations. Other ultrastructural lesions included dilated rough endoplasmic reticulum in hepatocytes. No hepatocyte necrosis or advanced degenerative changes were noted. In an accompanying experiment when CPA and a atoxin B 1 (AFB 1 ) were administered simultaneously, there was no indication of a synergistic effect when both toxins were administered. Animals treated with AFB 1 only developed more advanced liver lesions and died earlier than those that received high doses of CPA (Jaskiewicz et al. 1988) . Frank et al. (1977) conducted a series of studies with cheeses (given in the diet), a suspension of mold added to the diet, and an extract of mold injected subcutaneously. In the rst series, Sprague-Dawley rats were fed 5 days on cheese, followed by 2 days on commercial diet for the life time of the animals. The test groups were (1) 80 rats fed ve types of commercial Camembert or brie cheeses rotated weekly, (2) 60 rats fed a type of commercial blue cheese, (3) 60 rats fed a cheese identi ed as Camembert A, (4) 60 rats fed Camembert F, and (5) a control group of 21 animals. At the conclusion of the test, the mean consumption of cheeses by each animal in group 1 was 9.5 kg, group 2 was 8 kg, group 3 was 12.7 kg, and group 4 was 12.5 kg.
Chronic Toxicity and Carcinogenicity Studies 1
In the second series, the rats were gavaged with mold suspensions once each week for the life span of the rats. The test groups were (1) Camembert culture A (4.95 g mycelium/animal), (2) Camembert culture F (4.10 g mycelium/animal), (3) culture of P. camemberti var. candidum III C3 (6.23 g mycelium/animal);
(4) a blue cheese culture (4.80 g mycelium/animal), and (5) a control group that received normal saline. Each group consisted of 60 animals, except for the control which contained 21 animals.
In the third series the rats were injected subcutaneously once weekly for 52 weeks, observed for the remainder of the life span, and sacri ced. The test groups were (1) Camembert culture A (2.94 g mycelium/animal), (2) Camembert culture F (2.75 g mycelium/animal), (3) P. camemberti var. candidum III C3 (2.63 g mycelium/animal), (4) blue cheese culture (2.93 g mycelium/animal ), and (5) control group which received saline. All groups contained 60 animals, except the control which contained 44 animals. 1 In an often-quoted paper on CPA production by Aspergillus, Orth (1977) alleges that CPA is a carcinogenic mycotoxin. No empirical evidence was offered in support of this claim nor was another paper cited supporting this claim. Whether in response to, or independent of this comment, Frank, Orth, and others (Frank et al. 1977 ) conducted a series of experiments with molds known to produce CPA.
The rats showed no acute toxic lesions during the treatments described above. The rat weight development was within normal range. There was no indication of a carcinogenic or other detrimental effect (Frank et al. 1977) . Dorner (1987a, 1987b ) administered a single, oral pulse dose of CPA (15, 20, 30, 45, or 50 mg/kg) or ergonovine maleate (66 mg/kg) to mice on 1 day of days 2 to 8 of pregnancy. The sperm-or plug-positive day was considered to be day 1 of pregnancy and the mice were sacri ced on day 12 of gestation. Pregnant control mice received solvent only (1 N sodium bicarbonate). Ovaries and uteri with fetuses were removed and weighed. The number of implanted normal and resorbed fetuses and the corpora lutea were counted to determine the extent of pre-and postimplantation losses of ova due to the treatments. Fetuses with darker color and smaller than 50% of the normal size for day 12 of pregnancy were counted as resorbed fetuses. CPA decreased body weight gains and the weight of uteri with fetuses, but had no effect on ovarian weights. In control, 97.5% sperm-or plug-positive mice were gravid on day 12, whereas mice treated with CPA had signi cantly lower pregnancy rates; that is, CPA increased the number of mice with 100% inhibition of nidation of fertilized ova. In addition, vaginal hemorrhage (abortion) occurred in some mice treated with a single dose of CPA from days 4 to 8 of pregnancy; the hemorrhage being observed 1 to 7 days after treatment. The fetal resorption rate was increased only in the group treated with 30 mg/kg CPA on day 4 or 8 of pregnancy. Although increased resorptions were not seen at 45 or 50 mg/kg, at any interval, 30 mg/kg was likely a maternally toxic dose. Estrous cycle returned without any delay after CPA treatment in which nidation of fertilized eggs had been inhibited by CPA. Ergonovine maleate had no signi cant effects on all these parameters Dorner 1987a, 1987b) .
Reproductive Toxicity

Embryotoxicity and Teratogenicity
Cultured rat embryos have been used in some studies to evaluate the in vitro embryotoxicity of CPA. In a study by Small et al. (1991) , a 45-hour exposure of the embryos to CPA (0.01 mM) had no effect compared to control embryos, whereas ochratoxin A (0.025-0.25 mM) induced a dose-dependent reduction in embryonic DNA and protein content, somite number, crown-rump length, and yolk sac diameter. Interestingly, CPA enhanced the developmental toxicity of ochratoxin A in this assay system (Small et al. 1991) . In contrast to these results, Dryden et al. (1991) found that CPA (0-0.45 mM) produced the same effects on the rat embryos as did ochratoxin A in the study by Small et al. (1991) . Despite these ndings, as well as consistent anomalies of the mandibular process in embryos exposed to the highest concentrations, the authors concluded the CPA is not a potent teratogen in vitro (Dryden et al. 1991) .
Fungal contamination is a realistic problem in the process of mammalian in vitro fertilization techniques. Despite this, little is known of the effects mycotoxins may present to early embryonic development and only one report was located which examined CPA-mediated developmental toxicity. Svalander, Olovsson, and Holmes (1994) cultured four-cell embryos of NMRI mice in the presence of CPA for 5 days and observed developmental changes by microscopy. CPA (10 l g/ml) had no effect on the outgrowth of embryonic trophoblast cells but clearly inhibited the inner cell mass development (Svalander, Olovsson, and Holmes 1994) . Of 17 four-cell embryos exposed to either 0.1 or 10 l g/ml CPA, none exhibited normal blastocyst hatching and out-growth, whereas all embryos reached this end point following their incubation with 0.01 l g/ml CPA (Svalander et al. 1994) .
Embryotoxicity of a diverse range of mycotoxins has also been measured in a chick embryo assay system (Prelusky et al. 1989) . Following a single administration of fungal metabolite, the LD 50 values were based on mortality after an incubation period of 7 and 22 days (at hatch). The 37 mycotoxins tested had a 20,000-fold difference between the most lethal and least toxic (0.0124 to > 350 l g/egg), with CPA calculated to have an LD 50 in the range of 14 to 17 l g/egg (Prelusky et al. 1989) .
A teratology study was conducted by Khera et al. (1985) , wherein Swiss-Webster mice were paired with males and the presence of vaginal plug was considered day 1. Fifteen to 20 mated females per group received CPA by gavage in 1 N sodium bicarbonate at 4, 8, or 16 mg/kg for 4 consecutive days (from day 9 until day 12 of pregnancy). The volume of the test solution administered was 1.5, 3, or 6 ml/100 g for the 4, 8, or 16 mg/kg CPA dose levels, respectively. Control females were administered 6 ml of vehicle/100 g and were otherwise treated similarly as the test females. Dams were weighed on days 1, 9, 10, 11, 12 of pregnancy and at necropsy on the 19th day. No overt signs of toxicity or body weight suppression were noted. There was a slight decrease in incidence of pregnancy in all test doses, but the decrease was not dose related or statistically signi cant. The number of implants per animal, resorptions, resorption/implant ratio, dead fetuses, runted fetuses, live fetuses per pregnancy, or ratio of male to females was not different among treated and control groups. Fetal weight was decreased in the low-and middose groups, but not at the highest-dose group. There were no differences among treated and controls in the number of external or visceral malformations. There was a slight, but not statistically signi cant, increase in the number of retarded ossi cations and rudimentary 13th ribs in treated versus control animals. The authors considered that an effect level was not achieved (Khera et al. 1985) .
Eighteen-week-old female Fischer rats were bred with males and the presence of semen was noted as the 1st day of pregnancy. The rats were randomized into four groups of 16 each and received daily doses of 0, 4, 8, or 16 mg CPA/kg by intubation on days 8 to 11 of pregnancy. CPA was dissolved in 1 N sodium bicarbonate. Another 53 rats were dosed on days 12 to 15 of pregnancy. Survivors were sacri ced on day 21 of pregnancy. Signi cant decreases in feed consumption by the highest dosed dams of both groups were found. One high-dose rat within each group died prior to term and signs of toxicity were observed in other high-dose animals. Animals that died had histological lesions in the liver and spleen (focal areas of coagulative necrosis and single cell necrosis), kidney, salivary glands, and duodenum (minor lesions). There were no stomach abnormalities in any high-dose rats and most uteri and placentas were normal. Remaining dams were killed on day 21. Compared to controls, there were no signi cant differences in pup weights, percentage pre-or postimplantation losses, or fetal deaths. Signi cant differences in skeletal development included retardation of ossi cation of cervical centra (days 12-15 group) and caudal vertebrae (days 8-11 group) in the two higher-dose groups. Retardation of development were the most common manifestations of embryotoxicity. Because signi cant maternal toxicity occurred at the highest dose level in the absence of fetal malformations, the teratogenic potential of CPA is low (Morrissey et al. 1984a (Morrissey et al. , 1984b .
Mutagenicity Studies
Wehner et al. (1978) examined the potential mutagenicity of CPA in Salmonella typhimurium strains TA100, TA98, TA1535, and TA1537, both with and without metabolic activation by S9 hepatic microsomal fraction. There was no change in the incidence of revertants when incubated with 0, 0.25, 2.5, 25, or 250 l g CPA/plate. The authors concluded that CPA at these concentrations was not mutagenic in this assay system (Wehner et al. 1978) . These results were later con rmed in studies by Yates et al. (1987) using maximum concentrations of 11.1 l g CPA/ml, and by Takahashi et al. (1992) using 100 l g CPA/plate. Following S9 fraction metabolic activation, CPA was nonmutagenic to S. typhimurium strains TA98 (Yates et al. 1987 ) and TA100 (Takahashi et al. 1992) .
In contrast to these reports, Sorenson, Tucker, and Simpson (1984) found CPA to be mutagenic to both S. typhimurium strains TA98 and TA100 in the presence of metabolic activation (see Table 5 ). The conclusion that CPA is mutagenic to the TA100 strain is questionable because the maximum CPA concentration examined (1 l mol/plate) elicits an increase in the number of revertants only 1.4 times greater than the negative control. Therefore, the biological signi cance of this very small increase in S. typhimurium revertants per plate in TA100 remains questionable. Yates et al. (1987) suggested that the discrepancy between Sorenson et al. (1984) and others might be due to the differences in animal species from which the microsomal preparations were derived: Wehner et al. (1978) used rat liver preparations whereas Sorenson et al. (1984) used Syrian golden hamster liver. Alternatively, the presence of impurities, such as a atoxin, would also evoke the responses reported by Sorenson et al. (1984) . However, in the absence of additional information to qualify the response noted by Sorenson et al. (1984) , the compound must be considered to have elicited a positive response as noted in one of three Ames assays, the signi cance of which is questionable in the light of its irreproducibility. Yates et al. (1987) tested the genotoxicity of CPA and AFB 1 in a nonbioluminescent mutant of the marine bacterium, Photobacterium phosphoreum. CPA and/or AFB 1 diluted in culture medium was used to challenge cells and the reversion to a chemiluminescent phenotype was determined every 40 minutes over a test period of 18 hours. CPA (0.69-5.56 l g/ml) had no effect on the spontaneous reversion rate of the bacteria to a bioluminescent phenotype, but at 11.11 l g/ml the luminescence was completely inhibited. This inhibition by CPA was not necessarily considered a cytotoxic response as continued incubation of these cells for 3 days returned their population to control levels. Mycotoxin AFB 1 stimulated an early increase in bioluminescence as compared to untreated control cells and this induction was suppressed by 11.11 l g CPA/ml. From these results, the authors concluded that CPA is nongenotoxic in this assay system and does not enhance the genotoxicity of AFB 1 .
Cytotoxicity
In a cytotoxicity assay with Photobacterium phosphoreum, one milliliter of the test material (either CPA or AFB 1 ) diluted in medium to the appropriate concentration was used to challenge 2 £ 10 5 cells in solution and chemiluminescence determined every 40 minutes over a test period of 18 hours. Loss of chemiluminescence was considered evidence of cytotoxicity. The authors reported the EC 50 (concentration at which 50% of chemiluminescence is lost) decreased signi cantly from 5 to 10 minutes and again between the 10 and 15 minute points. The cytotoxicity for CPA was greater than that of AFB 1 . The EC 50 for AFB 1 and CPA assayed in combination changed signi cantly between 5 and 10 minutes and again between 15 and 20 minutes. Plots of activity indicated that independent actions for cytotoxicity were present, which may be antagonistic at some concentrations (Yates et al. 1987) . Nishie et al. (1988 Nishie et al. ( -1989 examined the toxicities of various mycotoxins to the protozoan Tetrahymena pyriformis. CPA was found to be relatively nontoxic to the organism with a reported mean inhibitory concentration (IC 50 ) of 10.5 § 0.442 l g/ml (Nishie et al. 1988 (Nishie et al. -1989 .
In the zone inhibition test, disks impregnated with CPA (10 l g/disk), or other mycotoxins, were placed within a culture, incubated for 18 to 24 hours and growth inhibition zones were measured. CPA inhibited the growth of B. brevis, B. cereus var. mycoides, B. cereus, B. megaterium, B. subtilis, B. thuringiensis, and B. pumilus. It was not effective against Streptococcus aureus, Pseudomonas uorescens, Listeria ivanovii, L. innocua, Eschiricheria coli, Salmonella typhimurium, or the yeasts Kluyveromyces marxianus, and Saccharomyces cerevisiae. (Madyastha et al. 1994) .
Immunomodulator y Studies
In vivo immune response studies Hill et al. (1986) administered CPA intraperitoneally to Sprague-Dawley rats at daily doses of 0.1, 1, and 5 mg CPA/kg for 28 days. Each group had three animals of each sex. The controls were given 0.5 ml of 1 N sodium bicarbonate intraperitoneally once daily for 28 days. The authors reported mortality and clinical signs consistent with other investigators. They reported that spleen weights did not differ between groups and that total protein, albumin, packed cell volume, and hemoglobin were not altered. The 1 and 5 mg/kg dose groups had higher neutrophil counts and lower mean eosinophil and lymphocyte counts than the controls. Bone marrow and cell ratios were normal. At 0.1 and 1 mg CPA/kg there was a reduction in antibody titer against sheep red blood cells 5 days after injection. The 0.1 mg/kg group also had a reduction in antibody titer 7 days after injection. By day 14, the treated groups had a signi cantly higher antibody titer than the control group. Splenic destruction or depletion of lymphocytes were not observed (Hill et al. 1986 ). Morrissey et al. (1985) (see also above) dosed male Sprague-Dawley rats for four consecutive days at 0, 0.2, 2.0, 4.0, and 8.0 mg/kg. Liver and spleen were more affected than other organs in the two highest-dose groups. Livers in these groups contained diffuse pyknotic nuclei. Focal areas of coagulative liver necrosis were found in some high-dosed rats . Spleens were hemorrhagic and the white pulp contained necrotic lymphocytes. Leukocyte counts were decreased in a dose-related manner in the two highest-dose groups .
White female guinea pigs weighing 450 to 500 g were divided into groups of ve animals each to receive daily oral doses of 0, 0.00625, 0.0125, 0.025, 0.05, 0.1, 0.2, 0.4, 0.8, 1.6, or 1.95 mg CPA for 30 days. On the 3rd day of dosing, all guinea pigs were sensitized with 0.25 ml intramuscular injections of heatkilled suspension of Mycobacterium tuberculosis strains PN, C, and DT. Twenty-ve days later, each living guinea pig was challenged with 0.1 ml intradermal injections of M. tuberculosis test antigen and the area of reaction measured 24 hours later. Although mortalities occurred in the 1.6 and 1.95 mg CPA/day groups, CPA did not affect cutaneous hypersensitivity among surviving animals as noted by the absence of changes in skin test reactivity. No changes in serum glycolic acid or serum complement were noted, indicating a lack of effect on humoral immunity (Richard et al. 1986 ). There was no mention of pathological change of the spleen as cited by others. Pier et al. (1989) also checked for a decrement in immune response. Eight guinea pigs per group were dosed orally (by capsule) with CPA (2.2 mg/kg) or a atoxin B 1 (0.045 mg B 1 /kg), singly or in combination (nine animals) for 21 days. There were no mortalities among the animals receiving CPA or a atoxin alone, whereas six of nine animals receiving both died. There was a signi cant difference in the average body weights of the CPA-treated and control animals on day 11, but not by day 21. Livers on gross examination were light grayish in color and gall bladders were enlarged. Histological examination revealed some vaculotive change in centrilobular hepatocytes. Reaction to intracutaneous PHA or delayed cutaneous hypersensitivity was not decreased in CPA-treated animals versus controls. In vitro culture of lymphocytes and response to PHA with CPA had no effect. No change from control was noted in the ability to produce either classical complement or antibodies (Pier et al. 1989 ). Corrier (1991) reviewed the status of ndings on CPA and other mycotoxins as affectors of the immune system. He concluded that little was known about the effects of CPA on immune responses. Lymphoid necrosis was reported in the bursa of Fabricius of chickens ) and in the spleen and lymph nodes of dogs after ingestion of CPA (Nuehring et al. 1985) . The recurrence of pneumonia in dogs after ingestion of CPA was attributed to lymphoid necrosis and concurrent suppression of immune resistance. The authors reported the presence of lymphoid necrosis, deceased mitotic activity in the intestinal epithelium, and the presence of cytomegaly in other tissues and suggested that lymphoid depletion and immunosuppression may be associated with impaired DNA and protein synthesis (Nuehring et al. 1985) . Antibody response to sheep red blood cells was decreased in rats injected intraperitoneally with CPA. However, CPA treatment had no effect on T cell-mediated delayed hypersensitivity response (Hill et al. 1986 ). The results of several studies have thus indicated that CPA may cause immunosuppression. The spectrum of CPA immunosuppressive activity remains unknown (Corrier 1991) .
In vitro immunomodulator y studies
The potential immunomodulatory effects of CPA have been more clearly examined in in vitro model systems. The majority of this work has focused on the stimulatory effect of CPA on in ammatory cytokines. Somewhat surprisingly, little in vivo research has been published which examines the relevance of these in vitro ndings. Akasaka et al. (1996) examined the effect of Ca 2+ -ATPase inhibitors on the calcium response, degranulation, and leukotriene C 4 release from the cultured rat basophil cell line, RBL-2H3.
CPA induced a concentration-dependent increase in [Ca 2+ ] i in the cells with a median effective concentration (ED 50 ) of 1.4 l M. b -Hexosaminidase release, an indicator of degranulation, was promoted by CPA in the presence of the protein kinase C activator 12-O -tetradecanoylphorbol-13-acetate (TPA), but not as effectively in the absence of TPA (Akasaka et al. 1996) . In contrast to these results, leukotriene C 4 release was stimulated by CPA (ED 50 = 5.4 l M), regardless of the presence or absence of TPA. Calphostin, a protein kinase C inhibitor, also had no inuence of the leukotriene C 4 release induced by CPA (Akasaka et al. 1996) .
A later study by this group of authors found similar differentially regulated effects of CPA in the RBL-2H3 cells (Onose et al. 1998) . CPA induced both interleukin-4 (IL-4) and monocyte chemotactic protein-1 (MCP-1) release with maximal effects at 3 l M. Lower and higher concentrations were not as effective inducers of IL-4 and MCP-1 release. Tumor necrosis factor-a (TNF-a ) release was also stimulated by CPA, but this effect required the presence of TPA, whereas the IL-4 and MCP-1 release did not (Onose et al. 1998 ). Marin et al. (1996) also reported a stimulatory effect of CPA on cytokine secretion in the WEHI-3 murine macrophage cell line. In the absence of endotoxin (lipopolysaccharide; LPS), CPA stimulated IL-6 secretion following 24 hours of incubation of the cells with 5000 ng CPA/ml (' 15 l M). Concentrations of 1000 ng/ml or lower did not induce Il-6 secretion, and neither IL-1b nor TNF-a secretion were promoted in these cells in the absence of LPS. Stimulation of WEHI-3 cells with 5 l g/ml LPS alone had little effect on IL-1b , IL-6, or TNF-a secretion, but these were signi cantly increased with the addition of 1000 ng CPA/ml to the LPS-stimulated cells. Induction of this cytokine response by CPA was accompanied by a proliferation of the cells and preceded by elevations in corresponding cytokine mRNA levels. Interestingly, in most assays the stimulatory properties of CPA on cytokine secretion were maximal at 1000 ng/ml, with 5000 ng/ml inducing a lesser response (Marin et al. 1996) .
Another study revealed a similar response pattern to CPA by the EL-4 murine thymoma cell line (Marin et al. 1996a ). IL-2 and IL-5 secretion by EL-4 cells was signi cantly increased by 50 to 1000 ng CPA/ml when cells were coincubated with phorbol-12myristate-13-acetate (PMA). Higher CPA concentrations were not as effective at stimulating IL-2 or IL-5 production and inhibited cellular proliferation.
In a study on BALB/c mouse peritoneal macrophages, Bost and Mason (1995) described in greater detail the early effects of CPA on IL-6 expression. Both CPA (15 l M) and thapsigargin (100 nM), a chemically unrelated Ca 2+ ATPase inhibitor, induced a rapid increase in cytosolic calcium levels. IL-6 mRNA expression was elevated in these cells within 15 minutes of stimulation with either CPA or thapsigargin, thereby indicating the rapidity of the macrophage response. Also, both ATPase inhibitors promoted similar IL-6 responses in the macrophages, providing evidence that the cytokine-inducing signal transduction mechanism of CPA is related to its alteration of Ca 2+ ux within the cell. Although the rise in IL-6 mRNA levels was rapid, the corresponding elevation in IL-6 secretion by the macrophages appeared to be less so, but the secreted concentrations were continually rising beyond 20 hours post-stimulation (Bost and Mason 1995) . It should also be noted that the responses elicited in the murine macrophage cells by CPA and thapsigargin were in the absence of any other stimulatory compound or endotoxin.
CPA-mediated increases in intracellular Ca 2+ have also been found to modulate the expression of inducible nitric oxide synthase (iNOS), an IL-1-regulated gene, in human articular chondrocytes (Geng and Lotz 1995) . Although other reports have indicated that CPA has the potential to increase IL-1 and TNFa expression and secretion (Marine et al. 1996) , CPA inhibited both IL-1-and TNF-a -induced NO release, with an IC 50 of approximately 3 l M (Geng and Lotz 1995) . Levels of iNOS protein, as well as iNOS mRNA, were also reduced following exposure of the cells to CPA. In contrast to these results, CPA induced cyclooxygenase II mRNA expression, which was further enhanced when used in combination with IL-1 (Geng and Lotz 1995) . These results indicate that CPA could further alter the immune response through regulation of 2 proin ammatory enzymes, iNOS and cyclooxygenase.
Ca 2+ -signaling events in human neutrophils was recently investigated by Zhang et al. (1999) . CPA-and thapsigarginmediated increases in cytosolic Ca 2+ signi cantly promoted the activity of cytosolic phospholipase A 2 at concentrations of 2.5 and 1 l M, respectively, but these compounds did not affect protein kinase C activity (Zhang et al. 1999) . These same concentrations of CPA and thapsigargin signi cantly increased arachidonic acid release from the neutrophils (Zhang et al. 1999) .
IL-3-dependent cells will undergo programmed cell death (apoptosis) upon removal of IL-3 from the culture medium. Palaga et al. (1996) reported that CPA (1-10 l M) suppressed apoptosis in FDC.P2 myeloid progenitor cells, IC-2 mast cell precursors, and the Ca/F3 pro-B cell line, but did not protect these cells against apoptosis induced by other stimuli, such as IL-2 deprivation or with Fas monoclonal antibody. Also, CPA exposure above the optimal levels induced cell death. This activity was not unique to CPA, as other Ca 2+ -ATPase inhibitors, such as thapsigargin, produced similar effects. Conditioned medium from CPA-treated cells signi cantly protected non-CPA-treated FDC.P2 cells in the absence of IL-3. These results suggest that CPA promotes the expression of a protective soluble factor. Further investigations revealed that CPA was inducing the expression of IL-4 in these cells, which was conferring the apoptoticresistant properties and promoting cellular proliferation (Palaga et al. 1996) .
In Vitro Studies
Numerous in vitro studies have been conducted that describe the range of activities of CPA under culture, or organ bath, conditions. In addition to these, an even greater number of studies have been published in which CPA was used merely as an experimental tool to increase intracellular calcium or block Ca 2+ -ATPase activity in order to observe speci c physiological events. It would not be prudent, or useful to the reader, to the summarize all of these studies here, and so the following paragraphs were written to re ect the diverse range of activity of CPA and to perhaps provide further insight to the potential in vivo effects of this compound.
Papillary muscles from young Broad Breasted White turkey poults were mounted in organ baths in modi ed Krebs-Henseleit solution and exposed to 6 l g/ml of CPA. There was a decrease in maximum contractile force, maximum contraction and relaxation velocity, time to peak contraction, and total time for muscle contraction, and relaxation (Miller et al. 1989a ). These altered performances appear to be intracellular changes partially associated with calcium availability and were irreversible, suggesting that pathophysiological changes had occurred following acute CPA exposure (Miller et al. 1989a ).
Fenske and Fink-Gremmels (1990) studied the effect of various mycotoxins on testosterone secretion by cultured interstitial cells from the testes of adult gerbils. There was a concentrationdependent inhibition of testosterone production by T-2 toxin. Citrinin and CPA had slight inhibitory effects, with statistical signi cance attained only at concentrations of 1.74 and 149 nM, respectively.
The activating effect of some strong carcinogens on pancreatic deoxyribonuclease was examined by Cole (1984) . The magnitude of deoxyribonuclease activation was dependent on the strength of carcinogenicity. In this assay system, CPA was found to be a weak activator of pancreatic deoxyribonuclease in comparison to versicolorin C or a atoxins B 1 , B 2 , and M 2 .
A potentially novel mechanism of endothelial cell-controlled vascular pressure has been uncovered through the use of CPA in isolated mesenteric vascular beds from diabetic rats, spontaneously hypertensive rats, or Wistar Kyoto rats (Kamata et al. 1997) . CPA (10 ¡ 8 -10 ¡ 4 M) induced the vasodilation of methoxamine-preconstricted arterial beds in age-matched control, hypertensive, diabetic, and Wistar Kyoto rats (EC 50 = 7.9-20 l M). The vasodilatation of the mesenteric arterial bed induced by CPA is not due to the production of prostaglandin I 2 , nitric oxide, or endothelium-derived hyperpolarizing factor, but that this effect requires the endothelial cell production of cyclic AMP, thereby suggesting the existence of a novel endothelium relaxing factor (Kamata et al. 1997) .
A similar study was conducted by Rahimian et al. (1997) in which CPA (0.1-30 l M) was found to relax precontracted aortic rings in a concentration-dependent manner. This relaxation was dependent on the presence of the endothelial layer. Aortic rings from female and estrogen-treated rats showed a greater relaxation response to CPA than did tissue from male or ovariectomized animals. Pretreatment of aortic rings with a nitric oxide synthase inhibitor altered the CPA response to a contraction, instead of a relaxation (Rahimian et al. 1997 ). This response is somewhat different from that described by Kamata et al. (1997) , possibly due to the different tissue type used. The results by Rahimian et al. (1997) suggest that CPA enhances an estrogen-mediated calcium entry into the aortic endothelial cells.
CPA-mediated vascular dilation appears to be strongly dependent on the presence of the endothelium. In the absence of the endothelial layer, rat arterial smooth muscle cells and aortic strips respond to CPA by contraction (Sekiguchi et al. 1996; Tostes et al. 1995) . Although the active site of CPA is considered to be the reticular Ca 2+ -ATPase pump, the Ca 2+ in ux responsible for the arterial smooth contraction appears to be derived from the extracellular space, rather than the sarcoplasmic reticulum stores. The addition of verapamil (Sekiguchi et al. 1996) or nifedipine (Tostes et al. 1995) , both inhibitors of voltage-gated dependent Ca 2+ channels, signi cantly decreases the CPA-induced contraction in isolated rat arterial smooth muscle cells or aortic strips. The degree of contraction by CPA is greater when the tissue is derived from hypertensive than from normotensive rats, suggesting a greater Ca 2+ in ux from voltage-gated channels in the hypertensive animals (Sekiguchi et al. 1996; Tostes et al. 1995) .
CPA has been used to study the role of intracellular calcium stores in oxytocin-induced rhythmic contractions of rat uterine smooth muscle cells (Kasai et al. 1994) . Oxytocin promotes the rise of intracellular Ca 2+ concentrations and subsequent contraction of the cell. This response was inhibited by CPA (IC 50 = 0.3 l M) only when the cells had not been subjected to Ca 2+ loading prior to assay. Only at very high concentrations (300 l M) was CPA able to inhibit the rhythmic contractions induced by 10 nM oxytocin, thereby indicating the possible inhibition by CPA of voltage-dependent Ca 2+ channels. From these results, the authors suggest that low concentrations of CPA inhibit the loading of calcium into reticulum stores but that these stores are not directly involved in the uterine rhythmic contraction phenomenon (Kasai et al. 1994) .
Meiotic maturation of oocytes is also heavily regulated by calcium and calcium uxes, although its mechanisms are still poorly de ned. Petr et al. (1997) used CPA to study the role of calcium in the regulation of metaphase I and II in porcine oocytes. The incubation of pig oocytes for 3 hours with CPA (25-100 nM) accelerated their maturation in a concentration-dependent manner, but higher doses proved to be degenerative. This accelerated process was re ected by a signi cant shortening of anaphase I, telophase I, and metaphase II stages. Maturation of the CPA-treated oocytes was completed up to 6 hours sooner than control. Timing and duration of the CPA application was important because a 3-hour exposure commencing earlier than 21 hours after oocyte isolation had no effect on the rate of maturation, and CPA (100 nM) exposure for as little as ve minutes could induce a signi cant acceleration in the oocyte maturation rate. Inhibition of CPA-accelerated oocyte maturation was accomplished with the use verapamil or heparin, indicating the role of extracellular calcium in the maturation process and suggesting that CPA mobilizes the release of intracellular calcium stores through the inositol triphosphate receptor pathway (Petr et al. 1997) .
The minimal effective concentrations of CPA that resulted in toxicity to adult hydra (Hydra attenuata) (MAC A ) and to regenerating arti cial hydra embryos (MAC-D) were 0.3 mg/L and 0.4 mg/L, respectively (Dryden et al. 1991) .
Reports of Accidental Poisonings
The death of 8 to 10 calves in Britain, showing symptoms of sway back and tremors in the hind quarters followed by convulsion and death was reported by Harrison (1971) . A sample of crushed barley was obtained and examined. The mold P. cyclopium was isolated and thin layer chromatographic examination indicated cyclopiazonic acid. A similar toxin has been isolated, in a case of death in dairy cows in the United States, from P. palitans (Harrison 1971) . Rao and Husain (1985) reported the isolation of CPA from grain in Utter Pradesh, India, which had caused symptoms of "kodua poisoning" in humans. The symptoms included sleepiness, tremor, and giddiness, which lasted 1 to 3 days and was followed by a complete recovery.
COMMENTS
Cyclopiazonic acid is a product of the ubiquitous genera of molds, Aspergillus and Penicillium. The molds are known to inhabit a number of food sources and may constitute parasitic infections of man and other animals. Few incidents of cyclopiazonic acid mycotoxicoses have been reported primarily because of the benign nature of the intoxication. The low levels produced under even ideal conditions, and its effects, are often disguised with concurrent a atoxicosis. Indeed, an undetermined amount of toxicity data may have been generated using a atoxin-contaminated CPA, thus accounting for the range of dose effects.
Cyclopiazonic acid is a potent, speci c, and reversible inhibitor of the sarcoplasmic and endoplasmic reticulum Ca 2+activated ATPase. It is a polar substance and intestinal absorption is aided experimentally with solubilization in sodium bicarbonate. In the natural state, mixed with feed, or as a contaminate of foodstuffs, absorption may be less rapid or complete. Following an oral administration, CPA has a half-life of approximately 30 hours and is excreted largely unchanged in the urine and feces.
Cyclopiazonic acid is not considered to be a potent acute toxin as its oral LD 50 is in the range of 30 to 70 mg/kg. Multiple-dose studies also show a range of effects in several species and among the mammalian models, the pig appears to be the most sensitive with a NOEL in the range of 1.0 mg/kg/day. The preponderance of evidence from the rat and other test animals supports this dose as a defensible estimate of a no-effect level.
The target organs of CPA toxicity appear to be striated muscle, hepatic tissue, and spleen with a localization in the former, although more apparent toxic change in the latter two. The toxicity and symptoms of CPA poisoning can be attributed to its ability to alter normal intracellular calcium ux through its inhibition of the reticular form of the Ca 2+ -ATPase pump.
CPA is not a teratogen in mice, although fetal resorptions were noted at maternally toxic doses. CPA is not considered a carcinogenic agent and the weight of evidence militates against its characterization as a mutagen. Despite CPA-induced pathological changes ascribed to the spleen or bursa of Fabricius, there does not appear to be an effect on the immune system. In vitro studies imply a potential immunomodulatory effect of CPA, but in all of those reports very high concentrations of CPA were required and none of these ndings have been supported with in vivo studies.
Therefore, based on a NOEL of 1 mg/kg/day and accounting for species variation, an appropriate acceptable daily intake (ADI) would be approximately 10 l g/kg/day or 700 l g/day for the average individual. In the context of human exposure, if the uppermost limit of CPA found in cheese is 4 l g/g and the average individual consumes 50 g of cheese daily, this allows an intake of 200 l g, less than one third of a traditionally established ADI.
